LOGIN  |  REGISTER
Astria Therapeutics

List of Medical Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 123.67
3.16 2.62
17.37M
1.74B
US$ 215.190B
US$ 518.62
2.46 0.48
1.82M
358.42M
US$ 185.880B
US$ 414.75
-10.23 -2.41
2.45M
377.49M
US$ 156.560B
US$ 103.64
-1.01 -0.97
8.34M
1.48B
US$ 153.390B
US$ 389.40
0.50 0.13
1.61M
382.16M
US$ 148.810B
US$ 190.05
-4.74 -2.43
3.97M
715.67M
US$ 136.010B
US$ 89.61
0.08 0.09
5.74M
1.28B
US$ 114.700B
US$ 709.80
-0.48 -0.07
475,102
124.90M
US$ 88.650B
US$ 178.85
-2.05 -1.13
3.36M
286.61M
US$ 51.260B
US$ 76.49
0.31 0.41
4.42M
586.60M
US$ 44.870B
US$ 87.35
0.39 0.45
1.74M
494.62M
US$ 43.210B
US$ 514.61
-4.10 -0.79
314,106
80.42M
US$ 41.380B
US$ 159.56
0.10 0.06
1.99M
238.68M
US$ 38.080B
US$ 257.92
1.50 0.58
853,959
146.63M
US$ 37.820B
US$ 83.89
-0.21 -0.25
2.46M
392.11M
US$ 32.890B
US$ 113.99
-2.37 -2.04
1.45M
284.06M
US$ 32.380B
US$ 160.63
-2.62 -1.60
2.22M
173.00M
US$ 27.790B
US$ 1.00
-10.83 -0.90
90,649
20.78M
US$ 24.830B
US$ 225.54
0.95 0.42
1.65M
98.37M
US$ 22.190B
US$ 243.72
-3.52 -1.42
561,348
83.70M
US$ 20.400B
US$ 284.23
0.78 0.28
338,180
70.37M
US$ 20.000B
US$ 138.90
-4.48 -3.12
1.34M
136.55M
US$ 18.970B
US$ 166.91
-1.27 -0.76
1.54M
111.64M
US$ 18.630B
US$ 93.19
-1.71 -1.80
2.35M
197.85M
US$ 18.440B
US$ 287.53
-9.39 -3.16
685,858
59.51M
US$ 17.110B
US$ 96.14
-1.79 -1.83
1.77M
158.30M
US$ 15.220B
US$ 210.18
-11.41 -5.15
1.34M
71.85M
US$ 15.100B
US$ 72.63
-0.63 -0.86
1.84M
199.51M
US$ 14.490B
US$ 63.99
-0.03 -0.05
1.51M
222.84M
US$ 14.260B
US$ 27.77
-0.12 -0.43
3.59M
513.18M
US$ 14.250B
US$ 30.17
0.29 0.97
721,875
437.53M
US$ 13.200B
US$ 143.54
-3.34 -2.27
1.58M
79.48M
US$ 11.410B
US$ 93.26
-2.32 -2.43
979,615
117.87M
US$ 10.990B
US$ 48.36
0.12 0.25
1.79M
216.56M
US$ 10.470B
US$ 60.91
0.26 0.43
8.26M
168.07M
US$ 10.240B
US$ 50.46
-1.75 -3.35
2.08M
188.64M
US$ 9.520B
US$ 311.87
-7.29 -2.28
370,688
28.74M
US$ 8.960B
US$ 230.38
0.20 0.09
398,611
38.73M
US$ 8.920B
US$ 154.47
-3.88 -2.45
505,571
54.22M
US$ 8.380B
US$ 154.48
-2.22 -1.42
465,223
49.12M
US$ 7.590B
US$ 116.25
-7.81 -6.30
1.02M
56.18M
US$ 6.530B
US$ 56.34
-1.21 -2.10
845,206
112.95M
US$ 6.360B
US$ 40.55
-1.64 -3.89
2.16M
151.53M
US$ 6.140B
US$ 46.46
-0.82 -1.73
1.72M
123.89M
US$ 5.760B
US$ 97.70
-1.30 -1.31
580,837
57.14M
US$ 5.580B
US$ 246.40
-3.48 -1.39
224,309
22.14M
US$ 5.460B
US$ 83.02
-1.52 -1.80
497,976
59.10M
US$ 4.910B
US$ 13.90
-0.28 -1.97
328,008
353.40M
US$ 4.910B
US$ 111.06
-2.53 -2.23
835,173
44.19M
US$ 4.910B
US$ 70.18
-3.42 -4.65
1.34M
69.19M
US$ 4.860B
US$ 79.97
0.00 0.00
0
58.56M
US$ 4.680B
US$ 136.24
0.48 0.35
414,964
31.93M
US$ 4.350B
US$ 57.49
-1.35 -2.29
1.23M
75.03M
US$ 4.310B
US$ 112.49
-2.15 -1.88
456,256
34.89M
US$ 3.920B
US$ 126.83
-1.14 -0.89
400,325
29.49M
US$ 3.740B
US$ 75.77
0.64 0.85
408,564
49.23M
US$ 3.730B
US$ 109.88
-2.64 -2.35
757,320
33.83M
US$ 3.720B
US$ 70.98
0.00 0.00
0
51.11M
US$ 3.630B
US$ 72.55
-0.90 -1.23
726,294
48.04M
US$ 3.490B
US$ 58.35
-0.58 -0.98
1.81M
55.33M
US$ 3.230B
US$ 11.06
-0.17 -1.51
1.09M
283.86M
US$ 3.140B
US$ 122.47
-2.25 -1.80
131,355
24.61M
US$ 3.010B
US$ 23.93
0.48 2.05
1.60M
104.50M
US$ 2.500B
US$ 41.98
-0.56 -1.32
497,321
54.53M
US$ 2.290B
US$ 35.17
-0.68 -1.90
596,665
59.92M
US$ 2.110B
US$ 79.77
-2.33 -2.84
118,546
22.59M
US$ 1.800B
US$ 16.02
-0.19 -1.17
1.01M
111.49M
US$ 1.790B
US$ 25.45
-1.23 -4.61
1.42M
67.63M
US$ 1.720B
US$ 10.49
-0.14 -1.32
1.20M
146.17M
US$ 1.530B
US$ 47.64
-1.61 -3.27
456,932
30.94M
US$ 1.470B
US$ 29.26
-0.49 -1.65
290,326
49.50M
US$ 1.450B
US$ 30.49
-0.36 -1.17
263,199
47.04M
US$ 1.430B
US$ 31.16
-0.95 -2.96
627,118
45.78M
US$ 1.430B
US$ 35.19
-0.73 -2.03
983,250
35.97M
US$ 1.270B
US$ 9.22
0.02 0.22
1.02M
134.95M
US$ 1.240B
US$ 24.90
-0.59 -2.31
183,160
49.60M
US$ 1.240B
US$ 41.57
-0.88 -2.07
257,643
28.92M
US$ 1.200B
US$ 13.09
0.00 0.00
0
83.72M
US$ 1.100B
US$ 1.35
-0.03 -2.17
2.52M
793.05M
US$ 1.070B
US$ 4.74
-0.12 -2.47
5.21M
217.04M
US$ 1.030B
US$ 15.10
-0.55 -3.51
207,088
67.27M
US$ 1.020B
US$ 20.83
-0.59 -2.75
403,186
47.84M
US$ 996.510M
US$ 14.77
-0.59 -3.84
1.63M
66.61M
US$ 983.830M
US$ 6.42
-0.30 -4.46
661,630
147.70M
US$ 948.230M
US$ 11.13
-0.85 -7.10
957,530
77.71M
US$ 864.910M
US$ 17.36
0.09 0.52
832,565
49.53M
US$ 859.840M
US$ 13.89
-0.21 -1.49
1.23M
60.92M
US$ 846.180M
US$ 6.24
-0.48 -7.14
1.86M
128.70M
US$ 803.090M
US$ 56.69
-0.76 -1.32
30,623
12.72M
US$ 721.100M
US$ 16.62
-0.13 -0.78
287,918
42.61M
US$ 708.180M
US$ 11.92
0.10 0.85
5.71M
55.68M
US$ 663.430M
US$ 7.75
-0.24 -3.00
829,150
76.61M
US$ 593.730M
US$ 41.24
-2.36 -5.41
619,605
13.57M
US$ 559.630M
US$ 15.58
-0.04 -0.26
215,277
35.82M
US$ 558.080M
US$ 22.01
-0.64 -2.83
120,726
24.77M
US$ 545.190M
US$ 17.78
-0.36 -1.98
272,779
30.44M
US$ 541.220M
US$ 11.22
-0.45 -3.86
436,660
46.24M
US$ 518.810M
US$ 11.28
-0.35 -3.01
665,359
45.54M
US$ 513.690M
US$ 16.54
-0.85 -4.89
458,808
28.87M
US$ 477.510M
US$ 0.58
0.01 2.47
15.62M
809.83M
US$ 467.270M
US$ 1.23
-0.02 -1.60
1.48M
361.24M
US$ 444.330M
US$ 30.21
-0.41 -1.34
67,548
14.30M
US$ 432.000M
US$ 10.63
-0.22 -2.03
275,487
39.18M
US$ 416.480M
US$ 6.26
-0.23 -3.54
380,151
66.36M
US$ 415.410M
US$ 1.87
0.02 1.08
2.47M
220.86M
US$ 413.010M
US$ 4.47
-0.35 -7.26
1.34M
92.18M
US$ 412.040M
US$ 1.37
-0.02 -1.44
4.44M
300.08M
US$ 411.110M
US$ 4.28
0.40 10.31
4.43M
93.56M
US$ 400.440M
US$ 3.13
-0.17 -5.15
705,798
126.66M
US$ 396.450M
US$ 11.25
-0.07 -0.62
655,900
34.83M
US$ 391.840M
US$ 5.65
-0.14 -2.42
178,965
62.90M
US$ 355.380M
US$ 8.69
-0.05 -0.57
1.07M
40.61M
US$ 352.900M
C$ 2.24
0.00 0.00
0
154.17M
C$ 345.340M
US$ 5.14
0.07 1.38
1.61M
63.82M
US$ 328.030M
US$ 14.22
-0.73 -4.88
76,729
22.79M
US$ 324.070M
US$ 1.78
-0.04 -2.20
6.25M
181.76M
US$ 323.530M
US$ 4.20
0.07 1.69
992,525
74.23M
US$ 311.770M
US$ 17.42
-0.18 -1.02
313,408
17.72M
US$ 308.680M
US$ 8.22
-0.06 -0.72
11,489
37.44M
US$ 307.760M
US$ 7.24
-0.61 -7.77
379,638
41.51M
US$ 300.530M
US$ 7.35
-0.03 -0.41
1.22M
40.64M
US$ 298.700M
US$ 9.06
-0.02 -0.22
132,395
32.80M
US$ 297.170M
US$ 6.49
-0.18 -2.70
202,268
39.52M
US$ 256.480M
US$ 5.37
-0.14 -2.54
480,348
46.65M
US$ 250.510M
US$ 3.66
-0.17 -4.44
511,889
66.11M
US$ 241.960M
US$ 6.70
-0.08 -1.18
217,126
35.86M
US$ 240.260M
US$ 3.20
-0.07 -2.14
1.39M
74.80M
US$ 239.360M
US$ 28.00
0.00 0.00
0
8.53M
US$ 238.840M
US$ 8.44
-0.22 -2.54
97,875
27.92M
US$ 235.640M
C$ 0.82
0.01 1.23
82,092
285.82M
C$ 234.370M
US$ 26.31
-1.25 -4.54
51,136
8.89M
US$ 233.900M
US$ 12.09
0.48 4.13
115,918
18.90M
US$ 228.500M
US$ 9.52
-0.49 -4.90
144,700
23.25M
US$ 221.340M
US$ 5.84
0.00 0.00
0
37.47M
US$ 218.820M
US$ 2.02
-0.13 -6.05
387,524
106.32M
US$ 214.770M
US$ 8.00
-0.35 -4.19
354,151
26.07M
US$ 208.560M
US$ 5.67
-0.12 -2.07
290,574
35.69M
US$ 202.360M
US$ 2.32
-0.06 -2.52
1.01M
86.00M
US$ 199.520M
US$ 3.50
-0.04 -1.13
76,384
51.70M
US$ 180.950M
US$ 55.52
-0.50 -0.89
19,281
3.25M
US$ 180.440M
US$ 4.60
-0.12 -2.54
29,625
37.98M
US$ 174.710M
US$ 6.35
-0.33 -4.94
170,868
26.89M
US$ 170.750M
US$ 5.64
-0.06 -1.05
74,044
30.05M
US$ 169.480M
US$ 13.10
-0.09 -0.68
27,696
11.90M
US$ 155.890M
US$ 3.37
0.07 2.12
131,896
46.14M
US$ 155.490M
US$ 7.00
-0.19 -2.64
145,765
21.86M
US$ 153.020M
US$ 18.23
-0.42 -2.25
52,711
8.39M
US$ 152.950M
US$ 46.19
-1.08 -2.28
24,455
3.26M
US$ 150.580M
US$ 1.34
-0.03 -1.84
960,341
103.01M
US$ 137.520M
US$ 5.17
-0.26 -4.79
433,420
26.43M
US$ 136.640M
US$ 3.41
-0.04 -1.16
22,748
39.33M
US$ 134.120M
US$ 8.02
-0.01 -0.12
27,481
16.52M
US$ 132.490M
US$ 3.15
0.06 1.94
277,796
40.26M
US$ 126.820M
US$ 1.12
-0.02 -1.75
732,167
108.20M
US$ 121.180M
US$ 2.41
0.13 5.48
165,273
49.50M
US$ 119.050M
US$ 5.48
0.07 1.29
158,012
20.98M
US$ 114.970M
US$ 3.05
-0.08 -2.40
103,185
35.94M
US$ 109.440M
US$ 2.92
-0.08 -2.67
187,106
36.70M
US$ 107.160M
US$ 0.66
0.02 2.33
480,889
156.55M
US$ 103.320M
US$ 14.80
-0.96 -6.09
169,344
6.95M
US$ 102.860M
US$ 16.01
-0.12 -0.74
90,827
6.17M
US$ 98.750M
US$ 2.47
-0.05 -1.98
1.24M
37.86M
US$ 93.510M
US$ 1.55
-0.04 -2.52
211,513
59.24M
US$ 91.820M
US$ 2.09
0.02 0.97
321,144
43.44M
US$ 90.790M
US$ 7.91
-0.15 -1.86
36,261
11.45M
US$ 90.570M
US$ 4.97
-0.28 -5.33
358,887
17.54M
US$ 87.170M
US$ 0.62
0.00 0.00
83,354
139.32M
US$ 86.380M
US$ 2.26
-0.02 -0.88
73,399
37.79M
US$ 85.410M
US$ 2.13
0.15 7.58
66,111
39.56M
US$ 84.260M
US$ 2.12
0.09 4.19
6,539
36.80M
US$ 77.830M
US$ 2.39
-0.02 -0.83
105,004
30.64M
US$ 73.230M
US$ 1.99
-0.06 -2.93
283,247
35.98M
US$ 71.600M
US$ 4.34
-0.10 -2.25
109,570
16.44M
US$ 71.350M
US$ 2.31
-0.06 -2.53
70,852
30.24M
US$ 69.850M
US$ 0.66
-0.02 -2.26
351,814
103.98M
US$ 68.730M
US$ 2.51
-0.16 -5.99
794,471
25.75M
US$ 64.630M
US$ 1.03
0.04 4.04
53,489
62.61M
US$ 64.490M
C$ 0.55
-0.04 -6.78
59,000
116.96M
C$ 64.330M
US$ 1.29
0.00 0.00
0
49.57M
US$ 63.950M
US$ 0.14
-0.002 -1.41
1.46M
453.51M
US$ 63.490M
US$ 3.50
0.00 0.00
0
18.00M
US$ 63.000M
US$ 1.02
0.01 0.99
408,684
59.82M
US$ 61.020M
US$ 1.76
-0.02 -0.85
280,780
34.35M
US$ 60.280M
US$ 0.92
-0.11 -10.68
1.03M
62.78M
US$ 57.760M
US$ 1.52
-0.04 -2.56
130,212
37.39M
US$ 56.830M
US$ 2.01
-0.10 -4.74
6,836
27.94M
US$ 56.160M
US$ 10.31
0.27 2.69
11,850
5.28M
US$ 54.440M
US$ 7.27
-0.12 -1.62
43,298
7.42M
US$ 53.940M
US$ 20.01
0.00 0.00
0
2.54M
US$ 50.830M
C$ 0.20
0.00 0.00
0
253.70M
C$ 50.740M
US$ 0.62
-0.0021 -0.34
279,496
78.48M
US$ 48.500M
US$ 4.70
0.00 0.00
0
10.07M
US$ 47.330M
US$ 0.32
0.0084 2.70
1.02M
146.56M
US$ 46.750M
C$ 0.39
0.00 0.00
6,200
119.77M
C$ 46.710M
US$ 1.27
-0.01 -0.78
55,414
33.81M
US$ 42.940M
US$ 4.75
0.14 3.04
11,684
9.03M
US$ 42.890M
US$ 0.83
0.07 9.33
647,988
49.82M
US$ 41.150M
US$ 3.65
0.07 1.82
21,064
10.60M
US$ 38.640M
US$ 0.69
-0.04 -5.48
74,881
54.25M
US$ 37.430M
US$ 1.41
-0.06 -4.08
727,432
25.62M
US$ 36.120M
US$ 1.61
-0.09 -5.29
34,499
21.33M
US$ 34.340M
US$ 5.82
0.09 1.57
533,162
5.89M
US$ 34.280M
US$ 2.04
0.00 0.00
0
15.37M
US$ 31.350M
US$ 0.69
-0.01 -2.00
414,715
44.46M
US$ 30.500M
C$ 0.32
0.00 0.00
0
90.89M
C$ 29.080M
US$ 0.88
-0.05 -5.64
469,444
32.53M
US$ 28.760M
C$ 0.24
0.005 2.17
273,166
113.22M
C$ 26.610M
C$ 0.26
0.005 2.00
175,219
103.95M
C$ 26.510M
C$ 0.34
0.02 4.62
20,000
77.41M
C$ 26.320M
C$ 0.09
0.00 0.00
12,000
301.79M
C$ 25.650M
C$ 0.15
0.005 3.45
127,000
166.00M
C$ 24.900M
US$ 3.14
0.15 5.02
334,700
7.46M
US$ 23.420M
US$ 14.51
0.32 2.26
10,604
1.51M
US$ 21.910M
US$ 1.26
-0.03 -2.33
810,182
16.79M
US$ 21.160M
US$ 0.45
-0.0029 -0.64
1.99M
44.21M
US$ 19.940M
US$ 0.66
-0.01 -1.54
54,989
29.94M
US$ 19.760M
US$ 0.80
0.02 2.56
23,076
23.56M
US$ 18.850M
US$ 1.09
-0.06 -5.22
143,138
17.18M
US$ 18.730M
US$ 2.42
0.03 1.26
43,018
7.65M
US$ 18.510M
US$ 0.31
0.00 0.00
0
52.24M
US$ 16.390M
C$ 0.05
0.00 0.00
0
320.55M
C$ 16.030M
US$ 2.67
0.00 0.00
0
5.89M
US$ 15.730M
US$ 3.26
0.02 0.62
173,537
4.64M
US$ 15.130M
US$ 2.15
0.01 0.47
86,276
6.91M
US$ 14.860M
C$ 0.24
-0.03 -9.43
194,108
60.55M
C$ 14.530M
US$ 2.04
0.00 0.00
0
7.09M
US$ 14.440M
US$ 0.45
0.02 5.78
158,760
31.90M
US$ 14.360M
US$ 0.73
0.0009 0.12
77,629
18.63M
US$ 13.620M
US$ 0.79
-0.0051 -0.64
285,601
17.00M
US$ 13.380M
C$ 0.06
0.00 0.00
3,000
227.04M
C$ 12.490M
US$ 0.61
0.00 0.00
0
19.01M
US$ 11.530M
US$ 3.43
0.03 0.88
68,167
3.36M
US$ 11.520M
US$ 0.71
0.05 6.78
1.53M
16.14M
US$ 11.460M
US$ 0.73
-0.01 -1.83
195,190
15.60M
US$ 11.390M
US$ 0.44
0.05 12.78
140,706
24.75M
US$ 10.790M
US$ 0.60
0.001 0.17
137,042
17.29M
US$ 10.390M
US$ 0.36
0.03 8.17
1.44M
28.46M
US$ 10.220M
US$ 0.28
0.0045 1.63
678,672
33.71M
US$ 9.440M
US$ 4.58
0.00 0.00
0
2.04M
US$ 9.340M
US$ 2.20
-0.05 -2.22
40,257
4.17M
US$ 9.170M
US$ 3.80
0.07 1.88
145,935
2.37M
US$ 9.010M
US$ 3.40
-0.02 -0.58
121,136
2.55M
US$ 8.670M
C$ 0.09
0.005 6.25
150,000
100.02M
C$ 8.500M
C$ 0.08
0.00 0.00
101,760
101.29M
C$ 8.100M
US$ 1.06
-0.02 -2.04
156,408
7.59M
US$ 8.030M
US$ 3.18
0.33 11.58
539,473
2.39M
US$ 7.600M
US$ 1.89
0.05 2.72
116,984
3.81M
US$ 7.200M
US$ 0.79
0.0085 1.09
198,838
8.93M
US$ 7.050M
US$ 1.58
-0.07 -4.24
186,149
4.02M
US$ 6.350M
US$ 8.90
0.51 6.08
60,734
700,000
US$ 6.230M
US$ 5.77
-0.04 -0.69
14,107
1.02M
US$ 5.890M
US$ 7.11
-0.27 -3.66
56,163
738,370
US$ 5.250M
C$ 0.11
0.00 0.00
0
48.23M
C$ 5.060M
C$ 0.04
0.00 0.00
0
122.72M
C$ 4.910M
C$ 0.05
0.00 0.00
0
96.48M
C$ 4.820M
US$ 0.67
-2.44 -78.46
326,153
7.04M
US$ 4.720M
US$ 2.50
-0.03 -1.19
74,476
1.86M
US$ 4.650M
US$ 2.86
-0.06 -2.05
83,854
1.61M
US$ 4.600M
US$ 0.06
0.00 0.00
0
73.90M
US$ 4.510M
US$ 0.76
-0.006 -0.78
27,579
5.85M
US$ 4.470M
C$ 0.08
0.00 0.00
0
56.81M
C$ 4.260M
US$ 3.91
-0.25 -6.01
31,040
1.08M
US$ 4.220M
US$ 0.34
0.00 0.00
0
11.88M
US$ 4.040M
US$ 4.04
-0.02 -0.49
12,230
965,899
US$ 3.900M
US$ 0.78
0.00 0.00
0
4.85M
US$ 3.780M
US$ 1.29
0.02 1.57
239,441
2.59M
US$ 3.340M
US$ 0.23
0.0083 3.71
6.32M
12.59M
US$ 2.920M
US$ 1.06
0.03 2.91
263,244
2.50M
US$ 2.650M
US$ 5.04
-0.11 -2.14
82,309
519,000
US$ 2.620M
US$ 1.42
0.00 0.00
0
1.82M
US$ 2.580M
US$ 0.99
-0.02 -2.18
9.29M
2.58M
US$ 2.550M
US$ 1.57
-0.04 -2.48
40,474
1.49M
US$ 2.340M
US$ 0.20
0.00 0.00
1,100
10.59M
US$ 2.120M
US$ 0.06
-0.05 -45.45
53,499
28.05M
US$ 1.680M
US$ 0.47
0.00 0.00
0
3.20M
US$ 1.520M
US$ 0.08
0.00 0.00
0
16.67M
US$ 1.370M
US$ 0.25
0.00 0.00
0
5.24M
US$ 1.320M
US$ 0.01
0.0059 83.10
362,100
96.71M
US$ 1.260M
US$ 0.10
0.00 0.00
0
10.62M
US$ 1.010M
US$ 0.03
0.00 0.00
0
25.29M
US$ 860K
US$ 1.15
0.00 0.00
0
418,049
US$ 481K
C$ 0.005
0.00 0.00
0
59.81M
C$ 299K
US$ 0.06
0.00 0.00
0
1.78M
US$ 100K
US$ 0.001
-0.0012 -54.55
100
29.91M
US$ 30K
US$ 0.00
0.00 0.00
0
40.35M
US$ -
US$ 0.00
0.00 0.00
0
15.85M
US$ -
US$ 0.00
-0.0003 -100.00
200
6.39M
US$ -
US$ 0.00
-0.0001 -100.00
5.60M
855.04M
US$ -
C$ 0.52
0.00 0.00
102,548
-
C$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest News From Medical Stocks


NanoVibronix Announces Financing of up to $50 Million Private Placement of Preferred Stock

Upfront $8 Million in Gross Proceeds and potential $40 million in Gross Proceeds from Exercise of Additional Investment Rights TYLER, Texas / Jul 18, 2025 / Business Wire / NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices for enteral feeding, pain management and urological conditions, today announced it has entered into a definitive agreement with an institutional investor for... Read more


CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection

Draft Policy Recognizes the Importance of Surveillance Testing for Early Detection of Allograft Rejection in Kidney, Heart, and Lung BRISBANE, Calif. / Jul 18, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced the release of... Read more


Exagen Appoints Chas McKhann to Board of Directors

CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most... Read more


RadNet’s Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD

Acquisition contributes iCAD's commercial, technology, and regulatory capabilities The acquisition positions DeepHealth with an industry-leading suite of AI-powered breast cancer image interpretation and workflow solutions The combination is expected to provide acceleration of AI adoption and expanded worldwide access to advanced breast cancer screening and diagnosis technologies LOS ANGELES, July 17, 2025 (GLOBE NEWSWIRE) --  RadNet, Inc. (NASDAQ:... Read more


Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock

Led by Strategic Industry Partner and Select Institutional Investors Proceeds Strengthen Balance Sheet and Support Commercialization of Innovation Strategy ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has entered into definitive agreements with investors for the sale of approximately $12.5 million of its shares of common... Read more


Hyperfine Announces the First Commercial Sales of the Next-Generation Swoop® System Powered by Optive AI™ Software

Following the recent clearance of the new Swoop® System, two leading hospitals in the United States have purchased the first commercial units, marking the launch of next-generation portable MR brain imaging. GUILFORD, Conn. / Jul 17, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced... Read more


Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care

WHO WHAT WHEN WHY Nuwellis, Inc. Termination of theREVERSE-HF clinicaltrial July 17, 2025 To redirect resources towardoutpatient markets where scalableimpact is highest. MINNEAPOLIS, July 17, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. today announced the termination of its REVERSE-HF clinical trial, a randomized post-market trial evaluating ultrafiltration vs. IV loop diuretic therapy for fluid management in hospitalized heart failure patients. This... Read more


Abbott Reports Second-Quarter 2025 Results

Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1 Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26 Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 basis point increase Reported operating margin of 18.4 percent of sales; adjusted operating margin of 22.9 percent, which reflects a 100 basis... Read more


Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM

EL MONTE, Calif. / Jul 17, 2025 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced it has received CE certification under the European Union (EU)’s In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR) for its germline next-generation sequencing (NGS) system, which includes FulgentExome and Fulgent... Read more


Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board

Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board members Q2 ’25 revenue anticipated to be $20.4 million and Company reiterates previously announced Q2 ‘25 gross margin guidance HOLLISTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced a CEO succession plan under which John... Read more


Intelligent Bio Solutions Accelerates Global Growth with SmarTest® Patch Agreement, Reinforces U.S. Expansion Path as FDA Approval Remains a Strategic Priority

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a new global distribution agreement with SMARTOX®, a Texas-based leader in drug and alcohol screening services, to bring its SmarTest Patch drug detection product to international markets outside of the United States (“U.S”) and Canada. This partnership... Read more


Thermo Fisher Scientific and Sanofi Expand Strategic Partnership to Enable Additional U.S. Drug Product Manufacturing

Thermo Fisher to Acquire Sanofi’s Steriles Manufacturing Site in Ridgefield, New Jersey to Produce Critical Medicines for Sanofi Enables Additional U.S. Manufacturing Capacity to Serve Increased Demand for Pharma/Biotech Customers WALTHAM, Mass. / Jul 16, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of their strategic partnership with Sanofi to enable additional U.S. drug product... Read more


Tempus AI Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software

CHICAGO / Jul 16, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-Low EF (ejection fraction) software, which uses AI to identify certain patients who may have a low left ventricular ejection fraction (LVEF). Tempus ECG-Low EF joins Tempus ECG-AF as the second... Read more


Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

 HENDERSON, Nev., July 16, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides an update on the significant commercial and scientific progress of its Nu.Q® Discover program. With an estimated total addressable market of $200 million annually [1], Nu.Q® Discover targets a smaller market than our other larger pillars, but it is proving to be a strong source of early revenue... Read more


Global POISE Study Reaches Milestone of 600 Orthopedic Implants in Pediatric Patients, Advancing Research on the Safety and Efficacy of OrthoPediatrics® Products

WARSAW, Ind., July 16, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced a significant milestone in the ongoing Global POISE (Pediatric Orthopedic Implant Safety and Efficacy) Study: more than 600 implants are now being observed across 300+ pediatric patients as part of this study. Global POISE is a multi-center, post-market,... Read more


Jin Medical Launches Production at Plant No. 3, Accelerating Global Delivery from the Chuzhou Manufacturing Facility

Beijing, China, July 15, 2025 (GLOBE NEWSWIRE) -- Jin Medical International Ltd. (Nasdaq: ZJYL) (“Jin Medical”, and together with all its subsidiaries, the “Company”), a Nasdaq-listed provider of rehabilitation medical equipment, announced today that its wholly owned subsidiary, ZhongJin Medical Equipment (Anhui) Co., Ltd. (“Zhongjin Anhui”), has officially launched production at Plant No. 3 of Zhongjin Anhui’s intelligent manufacturing facility in Chuzhou,... Read more


Globus Medical Introduces DuraPro™ with Navigation, a Next-Generation, Oscillating System Designed to Safeguard Delicate Tissue

AUDUBON, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the expanded Excelsius™ navigation capabilities of its next-generation oscillating system, DuraPro™, as the latest addition to the Power Portfolio, designed to advance procedural workflows through safety features and efficiency. “Our goal is to revolutionize the $550 million high-speed drill market with the introduction... Read more


Nuwellis Secures New U.S. Patent, Strengthening Its Position as a Leader in Fluid Management Innovation

WHO WHAT WHERE WHEN WHY Nuwellis, Inc. Issuance of U.S. Patent No. 12,357,734 United States Patent and Trademark Office July 15, 2025 To protect innovations in blood filtering system design and methods that support safe and precise fluid removal during ultrafiltration therapy. MINNEAPOLIS, July 15, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management solutions, today announced the issuance... Read more


Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2025 Financial Results

KIRKLAND, Wash., July 15, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the fourth quarter and fiscal year ended April 30, 2025. Financial Highlights Reported revenue of $17.2 million in Q4 FY25, an increase of 71% compared to the prior year period. Reported revenue of $59.8 million in FY25, an increase of 115% compared to FY24. Generated gross... Read more


Aspira Women's Health Announces Appointment of Jane Pine Wood to the Board of Directors

AUSTIN, TX / ACCESS Newswire / July 15, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (QTCQB:AWHL), an AI enhanced bio-analytical based women's health company focused on delivering the leading tools critical to gynecologic disease diagnostics and disease management, today announced the appointment of Jane Pine Wood to the Board of Directors, effective July 11, 2025. "We are pleased to welcome Jane Pine Wood to the Board of Directors," said Jack Fraser,... Read more


First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test

Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participants Shield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) PALO ALTO, Calif. / Jul 15, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer... Read more


bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic

One third of world’s smokers live in China, which has highest rate of lung cancer SAN ANTONIO / Jul 15, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the China National Intellectual Property Administration (CNIPA)... Read more


Intelligent Bio Solutions Adds Next-Gen Wearable for Extended Drug Detection to Product Offering, Strengthening Leadership in Non-Invasive Testing

NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of the SmarTest® Patch to its portfolio of non-invasive drug testing solutions. The SmarTest Patch is an innovative wearable device, developed by SMARTOX®, that enables continuous drug detection through sweat over a 7 to 10-day period.... Read more


AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention

Largest cardiac surgery device trial ever with 6,500 patients enrolled, this landmark trial evaluates the stroke reduction benefit with AtriClip devices for the over one million cardiac surgery patients globally without a preoperative Afib diagnosis MASON, Ohio / Jul 15, 2025 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management,... Read more


Aethlon Medical Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort

SAN DIEGO, July 15, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for Oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review and recommended advancing to the next patient cohort without modification. The... Read more


Quest Diagnostics Introduces Testing for Oropouche Virus

Diagnostic testing for emerging infectious disease associated with severe neurological affects SECAUCUS, N.J., July 15, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the launch of a new diagnostic laboratory test for the Oropouche virus, an emerging disease that is increasingly found in South and Central America and the Caribbean. "As one of the leading providers of laboratory testing, Quest plays... Read more


AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth

Med Tech franchise delivers third consecutive quarter of over 20% revenue growth Reported strong adjusted EBITDA in the fourth quarter resulting in positive adjusted EBITDA for full fiscal year 2025 Drove $16.2 million of free cash flow in the quarter as a result of strong topline growth and operational efficiency efforts LATHAM, N.Y. / Jul 15, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused... Read more


PROCEPT BioRobotics: Aquablation® Therapy’s Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule

SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced that Aquablation therapy was assigned a Category I code effective January 1, 2026. The 2026 Medicare Proposed Physician Fee Schedule (PFS) includes payment rates for a new Category I Current Procedural Terminology (CPT) code related... Read more


Sanuwave Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025)

Sanuwave is pleased to announce preliminary revenues of $10.1 million to $10.2 million for the second quarter ended June 30, 2025. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 revenue increased between 41% and 42% compared to Q2 2024. First half of 2025 revenue increased 50-51% vs first half of 2024. EDEN PRAIRIE, Minn., July 14, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a... Read more


Sanara MedTech Announces Launch of Tissue Health Plus Wound Care Provider Pilot Program

Pilot program designed to provide real-world evidence in the use of Tissue Health Plus’ technology platform FORT WORTH, TX, July 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets,... Read more


Varex Imaging Announces Non-intrusive Cargo Inspection Systems Orders Valued at $17 Million

SALT LAKE CITY / Jul 14, 2025 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) today announced that it has received orders for its high-energy non-intrusive cargo and vehicle inspection systems valued at approximately $17 million USD from international customers. The systems will be placed at strategic locations securing sea and land ports. Varex Imaging CEO, Sunny Sanyal, stated “We are pleased to announce additional orders this fiscal year for our Cargo Systems... Read more


NEXGEL and STADA AG Announce Expansion of Partnership for North America

LANGHORNE, Pa., July 14, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced expanding its partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health. The expansion includes the planned launch of digestive enzyme formulas and solutions targeting scars and stretch marks. As... Read more


Vivos Submitted the Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Clinic

Kennewick, WA, July 14, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a pioneer in Precision Radionuclide TherapyTM (PRnT) solutions, today announced the submission of its Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel®, a novel hydrogel-based radioactive therapy designed to deliver targeted radiation to solid tumors. This comprehensive submission, supported by extensive animal and human data, marks a... Read more


Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions

Proposed transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies to meet surgeons' needs  Acquisition expected to be neutral to adjusted earnings per share in 2025 – 2027 and accretive thereafter and to contribute to revenue growth beginning in 2027 WARSAW, Ind. and AUSTIN, Texas, July 14, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and... Read more


Quidelortho and Bühlmann Laboratories Announce Availability of Fecal Calprotectin (Fcal®) Turbo and Fecal Pancreatic Elastase (Fpela®) Turbo Assays On Vitros™ Systems As A Microtip™ Partnership...

Gastrointestinal biomarker tests enhance patient diagnosis of IBD and pancreatic insufficiency on leading clinical chemistry platforms SAN DIEGO, July 14, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") and BÜHLMANN Laboratories AG today announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems as an MPA. Both particle-enhanced turbidimetric immunoassays, the fCAL... Read more


Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growth Creates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion Increases annual recurring revenue to over 70% with over 80% of revenue coming... Read more


VentriPoint Diagnostics and Lishman Global Sign Non-binding Term Sheet Defining License for VMS+ Technology

Toronto, Ontario – TheNewswire - July 11, 2025 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”), (TSXV:VPT) is pleased to announce that it has signed a non-binding term sheet with Lishman Global Inc. outlining the exclusive , non-transferable license of Ventripoint technology for use within Lishman’s echocardiography image platform in the People’s Republic of China including the Special Administrative Regions of Hong Kong and Macao (the... Read more


Encision Reports Fourth Quarter Fiscal Year 2025 Results

BOULDER, CO / ACCESS Newswire / July 11, 2025 / Encision Inc. (OTC PINK:ECIA), a medical device company that owns the patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal year ended March 31, 2025. The Company posted quarterly net revenue of $1.52 million for a quarterly net loss of $47 thousand, or $(0.00) per diluted share. These results compare... Read more


SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

DENVER, July 10, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, today announced it has entered into a definitive agreement for the issuance and sale of an aggregate of 5,242,464 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.763 per share of common... Read more


Inspira Technologies Achieves All Key Objectives in Previously Announced Government Talks, Forging a Pathway to National Adoption and Global Scale-Up of the ART100

RA'ANANA, Israel, July 10, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has successfully achieved all key strategic objectives in its high-level talks with a government health authority, located outside of the United States, on July 8, 2025, a meeting previously announced by the Company on... Read more


Intuitive: Vessel Sealer Curved receives FDA clearance

Intuitive’s latest advanced energy instrument features a unique curved tip for enhanced precision SUNNYVALE, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food & Drug Administration (FDA) has cleared its latest innovation in advanced energy instrumentation for use with its multiport da Vinci systems. Vessel Sealer... Read more


Intelligent Bio Solutions to Present PK Study Data at Association for Diagnostics and Laboratory Medicine 2025 Clinical Lab Expo

Data shows excretion of codeine in fingerprint sweat INBS’ System is viable option for non-invasive diagnostic testing NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing and screening solutions, today announced that it will present its Pharmacokinetic (“PK”) study data at the Association for Diagnostics and Laboratory... Read more


OraSure Technologies Launches Novel Blood Collection Device for Proteomic Research

The device has the potential to transform proteomic discovery through extended protein stabilization and a simplified workflow for research BETHLEHEM, Pa., July 10, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the launch of its HEMAcollect™●PROTEIN product to meet the evolving needs of proteomic researchers. The product, developed... Read more


Avricore Health’s HealthTab™ Platform Expands to North Central London in Groundbreaking NHS Pharmacy-Led Cardiovascular Project

VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) is pleased to announce the expansion of its HealthTab™ platform into pharmacies in North Central London—making it the second NHS Integrated Care Board (ICB), after North East London, to join this groundbreaking initiative aimed at tackling health inequalities through cholesterol screening. Six (6) new HealthTab™ systems were deployed in... Read more


IceCure Medical Announces Commencement of Rights Offering

CAESAREA, Israel, July 10, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has commenced its previously disclosed rights offering (the "Rights Offering"). Pursuant to the Rights Offering, the Company is distributing to all holders of record of the... Read more


Integer Appoints Michael Coyle to Board of Directors

New Director Brings Extensive Medical Device Industry Leadership and Technology Experience to Integer Board  PLANO, Texas, July 10, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced it has appointed Michael Coyle to its Board of Directors. Coyle brings more than 40 years of leadership in the medical device industry to Integer and... Read more


IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors

WESTBROOK, Maine / Jul 10, 2025 / Business Wire / IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board of Directors, effective July 10, 2025. "We are excited to welcome Jay to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. “Jay is an accomplished executive who brings extensive strategic thinking... Read more


bioAffinity Technologies Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging

bioAffinity Technologies’ noninvasive sputum test revealed early-stage lung cancer when other diagnostic options were contraindicated SAN ANTONIO / Jul 09, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive, accurate tests for the detection of early-stage cancer, today released a new case study of a complex clinical case in which CyPath® Lung identified Stage 1A adenocarcinoma lung... Read more


Nanalysis Scientific Announces First Regulated Assay for Pharmaceutical Quality Control via Benchtop NMR Accepted by the United States Pharmacopeia (USP) and European Pharmacopeia (Ph. Euro)

CALGARY, AB, July 9, 2025 /CNW/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR instruments and MRI technology for industrial and research applications announces the publication in the National Formulary of the first regulatory certified assay for benchtop NMR – the Molar Substitution Determination in Hydroxypropyl Betadex USP-NF/Ph. Euro (1804). "Currently Nanalysis sells primarily into... Read more


Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease

Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J., July 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio&... Read more